Skip to content

Ketamine research published in 2026

Page 33 of 35: studies 641 to 660 of 700, newest first. Back to the ketamine overview

Studies

Transforming treatment-resistant depression (TRD) care in the Gulf Cooperation Council (GCC) countries: a narrative review of emerging therapies, advancements, and implementation barriers.

Annals of General Psychiatry January 21, 2026 Mohammed A Alhassan

Treatment-resistant depression (TRD) remains a major clinical challenge worldwide and across the Gulf Cooperation Council (GCC) countries, where the burden of mental health disorders continues to rise. Conventional TRD therapies, including antidepressants, augmentation strategies, and electroconvulsive therapy (ECT), often result in incomplete remission and are associated with significant...

Real-world comparison of intranasal racemic ketamine and esketamine in treatment-resistant depression: A retrospective observational study.

Journal of Affective Disorders January 21, 2026 Jan Sarlon, Deanne Thomi, Annette B Brühl et al. 1 citation

Treatment-resistant depression (TRD) imposes major individual and societal burden, with few therapeutic options. Intranasal esketamine is approved but limited by cost and accessibility, prompting interest in alternatives. To assess non-inferiority of racemic ketamine versus esketamine in a real-world setting. We performed a single-centre, retrospective observational study emulating a randomized...

Dose-dependent effects of esketamine on the prevention of propofol-induced injection pain: a randomized controlled trial

BMC Anesthesiology January 17, 2026 Danyun Fu, Yilei Shen, Hongyan Xiao et al.

BACKGROUND: In our previous study, we showed that a low dose of esketamine could alleviate propofol-induced injection pain during general anesthesia induction. However, the dose-response relationship of esketamine remains unclear. This study aims to evaluate the dose-dependent efficacy of esketamine in preventing propofol-induced injection pain. METHODS: In this double-blind, randomized...

Generation of enantiospecific monoclonal antibodies against (2R,6R)-hydroxynorketamine.

Bioorganic & Medicinal Chemistry January 17, 2026 Uriel Matthew Enriquez, Natalie M González Velázquez, Mohammad Mosharraf Hossain et al.

Antibodies against small psychoactive molecules have been developed for applications ranging from substance detection and overdose protection to mechanistic understanding of the actions of complex substance mixtures. In this study, we describe the design, synthesis, formulation, and animal testing of an initial immunogenic bioconjugate, as well as subsequent isolation of enantiospecific...

DOI: 10.1016/j.bmc.2026.118573 (opens in new tab) Full text (opens in new tab) Bioconjugate chemistry Hydroxynorketamine Monoclonal antibody development

Combining DNA methylation features and clinical characteristics predicts ketamine treatment response for PTSD.

iScience January 16, 2026 Amir Valizadeh, John D Roache, Xinyu Zhang et al. 2 citations

Post-traumatic stress disorder (PTSD) exhibits extensive clinical and biological variability, making treatment challenging. The Consortium to Alleviate PTSD (CAP)-ketamine trial, the largest randomized study of ketamine for PTSD, found no overall benefit of ketamine over placebo, underscoring the necessity to identify responsive subgroups. Using pre-treatment blood DNA methylation profiles and...

Predicting Cardiovascular Collapse in Critically Ill Patients During Intubation Induction: A Prospective Observational Study.

Medicina (Kaunas, Lithuania) January 15, 2026 Ömer Emgin, Gamze Taşkan, Aytuğ Yıldız et al.

Background and Objectives: The study aimed to evaluate the predictive significance of Shock Indices and induction agents in predicting the risk of Peri-Intubation Cardiovascular Collapse (PIC) during intubation in the ICU. Materials and Methods: A total of 130 patients were analyzed in the study after dividing them into 2 groups based on the definition of PIC as Patients with PIC and Non-PIC...

DOI: 10.3390/medicina62010177 (opens in new tab) Full text (opens in new tab) Ketamine Intensive care unit Peri-intubation cardiovascular collapse Propofol +1

Simulating Synaptic Pruning and Ketamine-Like Recovery in Depression: Insights from Consolidation Duration and Iterative Regimens on Resilience and Relapse

Zenodo (CERN European Organization for Nuclear Research) January 14, 2026 Ngo Cheung 1 citation preprint

Background: Major depressive disorder (MDD) is increasingly framed as a failure of neuroplasticity. Excessive synaptic pruning in adolescence can leave circuits fragile; later stress then unmasks the weakness, whereas ketamine and related compounds can quickly rebuild critical synapses. Clinical data show that a single treatment often gives short relief, while repeated courses reduce relapse....

DOI: 10.5281/zenodo.18246390 (opens in new tab) Consolidation business Robustness evolution Time point Stimulus psychology +5

Effect of a Constant Rate Infusion of Ketamine on a Variable Rate Infusion of Xylazine in Standing Horses Undergoing Ventriculocordectomy and Laryngoplasty.

Veterinary sciences January 12, 2026 Francisco Medina-Bautista, Juan Morgaz, Setefilla Quirós-carmona et al.

Standing sedation in horses provides immobilization and analgesia for surgery while avoiding the high risks of general anesthesia. Ketamine at subanesthetic doses may enhance sedation and reduce xylazine requirements, but evidence in clinical settings is limited. In a randomized blinded trial, we evaluated whether adding a low-dose ketamine infusion could reduce the xylazine dose required for...

Efficacy and Safety of Intravenous Esketamine in Elderly Patients Undergoing Laparoscopic Radical Prostatectomy.

Journal of Visualized Experiments January 9, 2026 Tingjun Zhang, Shujuan Yan, Hui Wang et al.

While perioperative esketamine use has grown increasingly prevalent, evidence supporting its efficacy and safety in elderly patients undergoing laparoscopic prostate cancer surgery remains limited. This retrospective study evaluated intravenous esketamine's performance in this population by analyzing 186 elderly patients treated between 2021 and 2024, divided into a control group (n = 91;...

Ketamine in Diabetes Care: Metabolic Insights and Clinical Applications.

Pharmaceutics January 8, 2026 Shiryn D. Sukhram, Majandra Sanchez, Ayotunde Anidugbe et al.

Background: Depression and diabetic neuropathy (DN) commonly complicate diabetes and impair glycemic control and quality of life. Ketamine and its S-enantiomer, esketamine, provide rapid antidepressant and analgesic effects, yet diabetes-related pathophysiology and co-therapies may modify exposure, response, and safety. Methods: We conducted a scoping review following PRISMA-ScR....

AMELIORATIVE EFFECTS OF SELECTIVE PDE-10 INHIBITORS AGAINST KETAMINE-MEDIATED SCHIZOPHRENIC OUTCOMES IN MICE

Asian Journal of Pharmaceutical and Clinical Research January 7, 2026 Ruchika Srivastava, Prabhat Singh, Ajeet

Objectives: Schizophrenia (SCZ) is characterized by significant impairments in perception and cognitive flexibility. Making accurate plans for therapy demands a deeper comprehension of the brain mechanisms behind these disorders. The purpose of our investigation is to analyze the protective effects of papaverine, a phosphodiesterase-10 inhibitor, on ketamine-induced SCZ -like behavioral and...

Ketamine and Esketamine for the Prevention of Delirium in Surgical Patients: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Journal of Intensive Care Medicine January 7, 2026 Nestor Cordeiro Dos Santos Neto, R. Rolim Neto, Esther Frota Gomes et al. 1 citation

BackgroundDelirium is a common and serious complication in critically ill and surgical patients, associated with increased morbidity, prolonged hospitalization, and long-term cognitive impairment. Ketamine and esketamine have been proposed as potential protective agents due to their anti-inflammatory, analgesic, and NMDA receptor-blocking properties.MethodsWe conducted a systematic review and...

DOI: 10.1177/08850666251410471 (opens in new tab) Ketamine Randomized controlled trial Incidence geometry Placebo +8

Real-world evaluation of change in depressive symptoms among patients with treatment-resistant depression treated with esketamine

BMC Psychiatry January 4, 2026 Carl D. Marci, Kruti Joshi, Stevan Geoffrey Severtson et al. 2 citations

Abstract Background Treatment-resistant depression (TRD) is often characterized by inadequate response to ≥ 2 oral antidepressant treatments of adequate dose and duration during a major depressive episode (MDE). Esketamine nasal spray (ESK) was approved by the US Food and Drug Administration in 2019 for TRD in conjunction with an oral antidepressant under a Risk Evaluation and Mitigation...

Ketamine-Related Deaths Registered in Scotland 2013–2024

Clinical Neuropsychopharmacology and Addiction January 4, 2026 Amira Guirguis, John Martin Corkery, Fabrizio Schifano

Background: Ketamine, a dissociative anaesthetic and non-competitive NMDA receptor antagonist, has legitimate medical applications. However, rising illicit use across the United Kingdom (UK) has been accompanied by growing reports of toxicity, dependence, and deaths. These have led to renewed policy discussions. Rationale and Aim: Previous national studies have reported ketamine-related deaths...

DOI: 10.53941/cna.2026.100001 (opens in new tab) Full text (opens in new tab) Ketamine Polysubstance dependence Public health Accidental +3

Esketamine Attenuates Postoperative Neurocognitive Disorder in Aged Mice: Associations with Bioenergetic Remodeling in Hippocampal CD11b-Enriched Cell Fractions and Glycolysis-Related Signaling.

Drug Design, Development and Therapy 2026 Di Liu, Guangchun Li, Hui Huang et al.

Postoperative neurocognitive disorder (PND) is a clinically important complication in older surgical patients. Microglial inflammatory activation is frequently accompanied by altered cellular metabolism, but whether esketamine-associated neuroprotection is accompanied by bioenergetic changes in hippocampal CD11b-enriched cell fractions remains incompletely understood. A tibial fracture model...

Paediatric Ketamine Bladder Case Report: A Burgeoning Problem in the Paediatric Population.

Case reports in pediatrics 2026 Shreya Kulkarni, Arjun Visa, Marita Isaac et al.

Ketamine misuse is an increasing public health concern among adolescents in the United Kingdom, with initiation reported as early as 14 years of age and a rapidly rising demand for drug and alcohol support services. Chronic ketamine misuse is associated with significant urological sequelae, including ketamine-induced uropathy, a condition increasingly encountered within paediatric and...

DOI: 10.1155/crpe/2254453 (opens in new tab) Full text (opens in new tab) Case report Ketamine abuse Ketamine-induced uropathy Paediatrics

Structure-based molecular modeling of a novel S-Remiketamine scaffold and derived arylcyclohexanone analogues: NMDA receptor dynamics, MM-GBSA ranking, and CES1-Oriented structural compatibility.

Frontiers in chemistry 2026 Ahmed A A M M Alkhatip, Usama Raza, Ehab Farag et al.

Short-acting ketamine-related scaffold design remains an important medicinal-chemistry problem, but computational studies require conservative interpretation until receptor, enzymatic, and pharmacokinetic validation is available. S-ketamine, S-Remiketamine, and R1-R20 analogues were assessed using ligand curation, NMDA receptor docking, cross-target docking, explicit-solvent molecular dynamics,...

Rewiring Speech in Autism: A Ketamine Infusion Hypothesis

Medical Research Archives 2026 Marco Pasquali, Martina Martins, Chana Simanowitz et al.

Autism Spectrum Disorder (ASD) is a neurodevelopmental condition marked by persistent social communication deficits and repetitive behaviors, with communication abilities ranging from nonverbal to verbally fluent yet socially impaired. These deficits, linked to disrupted neural connectivity in regions like the posterior superior temporal sulcus (pSTS), reward circuits, and dorsal/ventral speech...

Clinician-patient communication in esketamine and psychedelic-assisted treatments for depression: a scoping review of evidence, gaps, and clinical implications

2026 Vassilis Martiadis, Fabiola Raffone, Domenico de Berardis preprint

BACKGROUND: Treatment-resistant depression (TRD) affects approximately one-third of patients with major depressive disorder and represents a critical clinical challenge. Esketamine (S-ketamine, Spravato), approved by FDA and EMA since 2019, and psychedelic-assisted therapies (psilocybin, MDMA) share a pharmacological feature unique among approved psychiatric treatments: they induce altered...

Intravenous Ketamine in Suicidal Ideation in Depression

Journal of Medical Excellence 2026 Risha Jatal, Abhishek Samarth, Srushti Deulkar

A BSTRACT Major depressive disorder is commonly associated with suicidal ideation, while conventional antidepressants have a delayed onset of action. Ketamine has emerged as a rapid-acting antidepressant with potential anti-suicidal effects. This retrospective case series evaluated the effectiveness and tolerability of intravenous ketamine in patients with major depressive disorder and active...